These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31163467)

  • 1. [The Polypill - A Practicable Approach?].
    Thürmann PA; Kleinerüschkamp AG; Boehme P
    Dtsch Med Wochenschr; 2019 Jun; 144(11):715-718. PubMed ID: 31163467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study.
    Salam A; Praveen D; Patel A; Tewari A; Webster R
    Glob Heart; 2019 Sep; 14(3):303-310. PubMed ID: 31451238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence.
    Webster R; Grobbee D; Rodgers A
    Eur J Prev Cardiol; 2020 Mar; 27(4):437-440. PubMed ID: 31446790
    [No Abstract]   [Full Text] [Related]  

  • 7. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of polypill components in patients with type 2 diabetes mellitus.
    Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
    Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 10. Could the polypill improve adherence? The patient perspective.
    Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
    J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
    Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
    Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polypill treatments for cardiovascular diseases.
    Webster R; Rodgers A
    Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polypill for cardiovascular disease prevention.
    Dalton AR
    JAMA; 2013 Aug; 310(7):749. PubMed ID: 23989135
    [No Abstract]   [Full Text] [Related]  

  • 17. Polypill for cardiovascular disease prevention--reply.
    Smith R; McCready T; Yusuf S
    JAMA; 2013 Aug; 310(7):749-50. PubMed ID: 23989317
    [No Abstract]   [Full Text] [Related]  

  • 18. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
    Chao J; Bansilal S
    Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular polypill: time to rethink?
    Bondugulapati LN
    Curr Opin Lipidol; 2016 Oct; 27(5):537-8. PubMed ID: 27579548
    [No Abstract]   [Full Text] [Related]  

  • 20. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.